Falcipain Inhibitors Based on the Natural Product Gallinamide A Are Potent in Vitro and in Vivo Antimalarials.

A library of analogues of the cyanobacterium-derived depsipeptide natural product gallinamide A were designed and prepared using a highly efficient and convergent synthetic route. Analogues were shown to exhibit potent inhibitory activity against the Plasmodium falciparum cysteine proteases falcipain 2 and falcipain 3 and against cultured chloroquine-sensitive (3D7) and chloroquine-resistant (W2) strains of P. falciparum. Three lead compounds were selected for evaluation of in vivo efficacy against Plasmodium berghei infection in mice on the basis of their improved blood, plasma, and microsomal stability profiles compared with the parent natural product. One of the lead analogues cured P. berghei-infected mice in the Peters 4 day-suppressive test when administered 25 mg kg-1 intraperitoneally daily for 4 days. The compound was also capable of clearing parasites in established infections at 50 mg kg-1 intraperitoneally daily for 4 days and exhibited moderate activity when administered as four oral doses of 100 mg kg-1.

[1]  Leann Tilley,et al.  Artemisinin Action and Resistance in Plasmodium falciparum. , 2016, Trends in parasitology.

[2]  L. Kotra,et al.  Identification of novel class of falcipain-2 inhibitors as potential antimalarial agents. , 2015, Bioorganic & medicinal chemistry.

[3]  J. Gut,et al.  Synthesis and structure-activity-relationship studies of thiazolidinediones as antiplasmodial inhibitors of the Plasmodium falciparum cysteine protease falcipain-2. , 2015, European journal of medicinal chemistry.

[4]  A. Harvey,et al.  The re-emergence of natural products for drug discovery in the genomics era , 2015, Nature Reviews Drug Discovery.

[5]  J. Gut,et al.  Synthesis of gallinamide A analogues as potent falcipain inhibitors and antimalarials. , 2014, Journal of medicinal chemistry.

[6]  Honglin Li,et al.  Identification of diverse natural products as falcipain-2 inhibitors through structure-based virtual screening. , 2014, Bioorganic & medicinal chemistry letters.

[7]  M. Bogyo,et al.  The antimalarial natural product symplostatin 4 is a nanomolar inhibitor of the food vacuole falcipains. , 2012, Chemistry & biology.

[8]  Maria Marco,et al.  Falcipain inhibition as a promising antimalarial target. , 2012, Current topics in medicinal chemistry.

[9]  David J Newman,et al.  Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.

[10]  Y. Tu.  The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine , 2011, Nature Medicine.

[11]  J. Golenser,et al.  Coincident parasite and CD8 T cell sequestration is required for development of experimental cerebral malaria. , 2011, International journal for parasitology.

[12]  Juan Miguel,et al.  Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. , 2010, Journal of medicinal chemistry.

[13]  John E. Bercaw,et al.  NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and Gases in Deuterated Solvents Relevant to the Organometallic Chemist , 2010 .

[14]  Honglin Li,et al.  Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening. , 2009, Journal of medicinal chemistry.

[15]  V. Paul,et al.  Combinatorial Strategies by Marine Cyanobacteria: Symplostatin 4, an Antimitotic Natural Dolastatin 10/15 Hybrid that Synergizes with the Coproduced HDAC Inhibitor Largazole , 2009, Chembiochem : a European journal of chemical biology.

[16]  M. Leippe,et al.  Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors. , 2009, Journal of medicinal chemistry.

[17]  Linda S. Brinen,et al.  Structures of Falcipain-2 and Falcipain-3 Bound to Small Molecule Inhibitors: Implications for Substrate Specificity‡ , 2009, Journal of medicinal chemistry.

[18]  J. Gut,et al.  Design and synthesis of novel 2-pyridone peptidomimetic falcipain 2/3 inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[19]  K. S. Lam,et al.  New aspects of natural products in drug discovery. , 2007, Trends in microbiology.

[20]  David A. Fidock,et al.  Antimalarial drug discovery: efficacy models for compound screening , 2004, Nature Reviews Drug Discovery.

[21]  P. Rosenthal,et al.  Cysteine proteases of malaria parasites: targets for chemotherapy. , 2002, Current pharmaceutical design.

[22]  Ashutosh Kumar Singh,et al.  Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. , 2001, The Biochemical journal.

[23]  P. Rosenthal,et al.  Systematic optimization of expression and refolding of the Plasmodium falciparum cysteine protease falcipain-2. , 2001, Protein expression and purification.

[24]  Abraham Nudelman,et al.  NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities. , 1997, The Journal of organic chemistry.

[25]  P. Rosenthal,et al.  Cysteine proteinase inhibitors block early steps in hemoglobin degradation by cultured malaria parasites. , 1996, Blood.

[26]  P. Rosenthal,et al.  Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase , 1995, Infection and immunity.

[27]  L. F. Fajardo,et al.  Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. , 1987, Science.

[28]  W. Peters.  Drug resistance in Plasmodium berghei Vincke and Lips, 1948. I. Chloroquine resistance. , 1965, Experimental parasitology.

[29]  A. Persidis.  Malaria , 1828, Nature Biotechnology.

[30]  Roger G. Linington,et al.  Antimalarial peptides from marine cyanobacteria: isolation and structural elucidation of gallinamide A. , 2009, Journal of natural products.